1
|
Sundar S, Khetrapal-Singh P, Frampton J, Trimble E, Rajaraman P, Mehrotra R, Hariprasad R, Maitra A, Gill P, Suri V, Srinivasan R, Singh G, Thakur JS, Dhillon P, Cazier JB. Harnessing genomics to improve outcomes for women with cancer in India: key priorities for research. Lancet Oncol 2019; 19:e102-e112. [PMID: 29413464 DOI: 10.1016/s1470-2045(17)30726-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2017] [Revised: 08/03/2017] [Accepted: 09/11/2017] [Indexed: 02/08/2023]
Abstract
Cumulatively, breast, cervical, ovarian, and uterine cancer account for more than 70% of cancers in women in India. Distinct differences in the clinical presentation of women with cancer suggest underlying differences in cancer biology and genetics. The peak age of onset of breast and ovarian cancer appears to be a decade earlier in India (age 45-50 years) than in high-income countries (age >60 years). Understanding these differences through research to develop diagnosis, screening, prevention, and treatment frameworks that ar e specific to the Indian population are critical and essential to improving women's health in India. Since the sequencing of the human genome in 2001, applications of advanced technologies, such as massively parallel sequencing, have transformed the understanding of the genetic and environmental drivers of cancer. How can advanced technologies be harnessed to provide health-care solutions at a scale and to a budget suitable for a country of 1·2 billion people? What research programmes are necessary to answer questions specific to India, and to build capacity for innovative solutions using these technologies? In order to answer these questions, we convened a workshop with key stakeholders to address these issues. In this Series paper, we highlight challenges in tackling the growing cancer burden in India, discuss ongoing genomics research and developments in infrastructure, and suggest key priorities for future research in cancer in India.
Collapse
Affiliation(s)
- Sudha Sundar
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
| | | | - Jon Frampton
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
| | | | | | - Ravi Mehrotra
- National Institute of Cancer Prevention and Research, Noida, Uttar Pradesh, India
| | - Roopa Hariprasad
- National Institute of Cancer Prevention and Research, Noida, Uttar Pradesh, India
| | - Arindam Maitra
- National Institute of Biomedical Genomics, Kolkata, West Bengal, India
| | - Paramjit Gill
- Institute of Applied Health, University of Birmingham, Birmingham, UK
| | - Vanita Suri
- Department of Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Radhika Srinivasan
- Department of Pathology and Cytology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Gurpreet Singh
- Department of Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - J S Thakur
- Department of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | | | - Jean-Baptiste Cazier
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Centre for Computational Biology, University of Birmingham, Birmingham, UK
| |
Collapse
|